Galecto, Inc. (GLTO)
NASDAQ: GLTO · IEX Real-Time Price · USD
0.621
-0.009 (-1.41%)
At close: May 17, 2024, 4:00 PM
0.622
+0.001 (0.16%)
After-hours: May 17, 2024, 6:24 PM EDT
Company Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Galecto, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Hans T. Schambye M.D., Ph.D. |
Contact Details
Address: 75 State Street, Suite 100 Boston, Massachusetts 02109 United States | |
| Phone | 45-70-70-52-10 |
| Website | galecto.com |
Stock Details
| Ticker Symbol | GLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001800315 |
| CUSIP Number | 36322Q107 |
| ISIN Number | US36322Q1076 |
| Employer ID | 37-1957007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Jonathan P. Freve CPA, CPA | Chief Financial Officer |
| Ulf J. Nilsson | Co-Founder |
| Dr. Hakon Leffler | Co-Founder |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Garrett Winslow Esq. | Senior Vice President, General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 8, 2024 | 10-K | Annual Report |
| Feb 9, 2024 | SCHEDULE 13G/A | Filing |
| Dec 21, 2023 | 8-K | Current Report |
| Nov 6, 2023 | 10-Q | Quarterly Report |
| Oct 23, 2023 | 8-K | Current Report |